Lantheus (NASDAQ:LNTH) Shares Up 4.4% - Should You Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report)'s share price rose 4.4% during trading on Monday . The company traded as high as $110.98 and last traded at $111.01. Approximately 721,991 shares were traded during trading, a decline of 21% from the average daily volume of 916,695 shares. The stock had previously closed at $106.34.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of analyst reports. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and a consensus price target of $132.86.

Lantheus Stock Performance

The company has a 50-day simple moving average of $91.87 and a 200-day simple moving average of $96.90. The company has a market cap of $6.90 billion, a price-to-earnings ratio of 16.74 and a beta of 0.38.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Lantheus

Several hedge funds have recently bought and sold shares of LNTH. Janus Henderson Group PLC increased its position in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Lantheus during the fourth quarter worth $36,183,000. Finally, Groupama Asset Managment acquired a new stake in shares of Lantheus during the third quarter worth $439,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.